Todas las fotos(1)

Documentos

1269618

USP

Fenofibrate Related Compound B

Name: Fenofibrate Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, Fenofibric acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₁₇H₁₅ClO₄

Número de CAS:

42017-89-0

Peso molecular:

318.75

Beilstein:

2058973

Número MDL:

MFCD00792461

Código UNSPSC:

41116107

ID de la sustancia en PubChem:

329749839

NACRES:

NA.24

Productos recomendados

Slide 1 of 10

1 of 10

USP

1269607

Fenofibrate Related Compound A

USP

1269629

Fenofibrate Related Compound C

Supelco

PHR2864

Fenofibrate Related Compound A

USP

1184027

Diatrizoic Acid Related Compound A

USP

1269447

Fenofibrate

USP

1356337

Ketorolac Related Compound C

USP

1165656

Deferasirox

USP

1269028

Ezetimibe

F0048005

Fenofibrate impurity A

USP

1584003

Pyrantel pamoate

grado

pharmaceutical primary standard

familia API

fenofibrate

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

O=C(C1=CC=C(OC(C)(C)C(O)=O)C=C1)C2=CC=C(Cl)C=C2

InChI

1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

Clave InChI

MQOBSOSZFYZQOK-UHFFFAOYSA-N

Información sobre el gen

human ... PPARA(5465)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Materiales de referencia

Patrones de las farmacopeas y de los institutos metrológicos

Patrones de referencia analítica | Sigma-Aldrich

Química analítica

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Fenofibrate Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Fenofibrate
Fenofibrate Capsules
Fenofibrate Tablets

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto

Descripción

Precios

1269447

Fenofibrate, United States Pharmacopeia (USP) Reference Standard

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

PHR2864

Pictogramas

GHS07,GHS09

Palabra de señalización

Warning

Frases de peligro

H302,H410

Consejos de prudencia

P264 - P270 - P273 - P301 + P312 - P391 - P501

Clasificaciones de peligro

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.

Roger K Verbeeck et al.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 18(1), 61-67 (2015-04-17)

The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. Most of these formulations show a higher bioavailability

Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.

Yunxia Lu et al.

Biochemical and biophysical research communications, 458(1), 1-7 (2015-01-17)

Fenofibrate (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley rats

Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.

Martin J A Schackmann et al.

Biochimica et biophysica acta, 1851(2), 231-237 (2014-12-17)

X-linked adrenoleukodystrophy (X-ALD) is a neurometabolic disease that is caused by mutations in the ABCD1 gene. ABCD1 protein deficiency impairs peroxisomal very long-chain fatty acid (VLCFA) degradation resulting in increased cytosolic VLCFA-CoA levels, which are further elongated by the VLCFA-specific

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico